Cholesterol - Articles and news items

Wilshire technology logo

Parenteral grade, vegetable-derived Cholesterol (FDA DMF 29599)

Supplier news / 7 September 2016 / Wilshire Technologies

The virtues of vegetal- vs. animal-derived actives and excipients are well-known and need no elaboration…

ESC launches new concept for driving innovation in cardiovascular research with exclusive support from Boehringer Ingelheim

New data adds to understanding of Repatha® (evolocumab) in multiple patient populations

Industry news / 23 August 2016 / Amgen

Amgen will present data evaluating Repatha® (evolocumab) at the upcoming European Society of Cardiology (ESC) Congress 2016 in Rome…

SPIRE-HR and SPIRE-FH trials of bococizumab meet primary endpoints

Industry news / 28 June 2016 / Victoria White, Digital Content Producer

Two Phase III trials of Pfizer’s bococizumab, SPIRE-HR (HighRisk) and SPIRE-FH (Familial Hypercholesterolemia), met their primary endpoint…

Positive results for Praluent in patients undergoing LDL apheresis therapy

Industry news / 23 March 2016 / Victoria White

Patients who added Praluent to their existing treatment regimen significantly reduced the frequency of their apheresis therapy by 75% compared to placebo….

Heart UK questions absence of lipidologists after NICE limits cholesterol-busting drug use

Industry news / 12 February 2016 / Victoria White

Heart UK has questioned why the NICE did not seek the expertise of lipidologists during its latest review of PCSK9 cholesterol-busting drugs…

NICE says ‘no’ to alirocumab in draft guidance

Industry news / 8 February 2016 / Victoria White

NICE was concerned that alirocumab had not been compared with the combination therapy of ezetimibe plus a statin and that trials of the drug were not able to provide robust information on cardiovascular outcomes…

Positive topline results from GAUSS-3 trial of Repatha

Industry news / 5 February 2016 / Victoria White

The Phase 3 GAUSS-3 trial evaluating Amgen’s Repatha (evolocumab) in patients with high cholesterol who cannot tolerate statins met its co-primary endpoints…

NICE says ‘no’ to Amgen’s Repatha in draft guidance

Industry news / 18 November 2015 / Victoria White

The NICE Committee felt the question whether Repatha (evolocumab) would reduce angina, heart attacks and strokes remains unanswered…

EC approves LDL cholesterol treatment Praluent

Industry news / 28 September 2015 / Victoria White

Praluent is the only EC-approved PCSK9 inhibitor that is available in two starting doses, offering two levels of efficacy…

FDA approves LDL cholesterol drug Repatha

Industry news / 28 August 2015 / Victoria White

Repatha, the second drug approved in a new class of drugs known as PCSK9 inhibitors, has been approved by the FDA for some patients who are unable to get their LDL cholesterol under control with current treatment options…

FDA approves Praluent for the treatment of high LDL cholesterol

Industry news / 26 August 2015 / Victoria White

The US Food and Drug Administration (FDA) has approved Praluent (alirocumab) Injection – the first and only PCSK9 inhibitor approved in the US…

EC approves Amgen’s cholesterol-lowering medication Repatha

Industry news / 21 July 2015 / Victoria White

The EC has granted marketing authorisation for Repatha for the treatment of patients with uncontrolled cholesterol who require additional LDL-C reduction…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...